A downtrend has been apparent in Intellia Therapeutics, Inc. (NTLA) lately with too much selling pressure. The stock has declined 19.1% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical in ...

Companies focusing on developing gene editing therapies have made significant progress over the past year. However, that has done little to keep Intellia Therapeutics (NTLA -1.63%) afloat. The biotech's stock has substantially lagged the broader market over the trailing 12 months. Still, Intellia Therapeutics has several promising candidates in the pipeline. If the company can record solid clinical and regulatory progress from here on out, its stock could rebound. Does Intellia Therapeutics have what it tak ...

SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa Positive recommendation received from the Data Safety Monitoring Board (DSMB) enabling progression to highest dose of Part 1 of the PRODYGY trialFavorable safety and tolerability profiles observed with first two SPVN06 doses across six patients (three patients per cohort)Exploration of SPVN06 in geographic atrophy to begin in 2024 Paris, 24 January 2024 – SparingVision ("the Company"), a clinical-stage gen ...

One stock that might be an intriguing choice for investors right now is Intellia Therapeutics, Inc. (NTLA) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably t ...

Core priorities through 2026 include completion of Phase 3 study and BLA submission for NTLA-2002, completion of patient enrollment in the pivotal study of NTLA-2001, clinical validation of modular in vivo gene insertion technology and advancement of earlier-stage pipeline and platform innovations On track to dose the first patient in the pivotal Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy in Q1 2024Expect to present results from the Phase 2 ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Ian Karp - SVP, IR and Corporate Communications John Leonard - President and CEO David Lebwohl - EVP and CMO Laura Sepp-Lorenzino - EVP and CSO Glenn Goddard - EVP and Chief Financial Officer Eliana Clark - EVP and CTO Conference Call Participants Kostas Biliouris - BMO Capital Markets Joon Lee - Truist Securities Mani Forooher - Leerink Partners Unidentified Analyst - Guggenheim Partn ...

Intellia Therapeutics' Legal Disclaimer 3 Agenda Clinical Pipeline Updates Q3 Financials Summary 4 Agenda Dr. John Leonard Chief Executive Officer Glenn Goddard Chief Financial Officer | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------|-----------------------------------------------------------|---------------------------------------------------|-----------------------------------------------------------------------|------------------------ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4785571 (State or Other Jurisdict ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Ian Karp - SVP, IR and Corporate Communications John Leonard - President and CEO David Lebwohl - EVP and CMO Laura Sepp-Lorenzino - EVP and CSO Glenn Goddard - EVP and CFO Conference Call Participants Maury Raycroft - Jefferies Unidentified Analyst - RBC Capital Joseph Thome - TD Cowen Mary Kate - Bank of America Unidentified Analyst - Truist Securities Unidentified Analyst - Barclays De ...

Return to Appendix Table of Contents | --- | --- | |-------------|----------------------------------------------------------------------------------------------------------------------------------| | | | | Increasing | • Leveraging our technology while retaining rights to key areas of focus | | shareholder | • Accelerate development of programs outside key areas of focus | | value: | • Expand our pipeline with valuable rights in future commercial success • Access external expertise to enhance our platform | ...